News posts that will display on the Homepage and News Category.
Scientists at USC and UC San Diego have discovered a potential novel target for treating glioblastoma. “We think this is opening the door to a whole new range of therapies,” said Steve Kay. “It’s a great example of collaboration and convergence.” (August 27, 2019)
Students attribute Fulbright opportunities to study diabetes and cancer to research experience gained at the Bridge Institute at the USC Michelson Center for Convergent Bioscience. (May 9, 2019)
Researchers plan to develop new sleep disorder treatments based on new 3D models of two melatonin receptors created by an international team. The studies were published in ‘Nature.’ (April 24, 2019)
The director of the USC Michelson Center for Convergent Bioscience and the MESH Academy becomes the university’s second faculty member in the prestigious society. (April 18, 2019)
Scientists at USC Michelson Center for Convergent Bioscience and Japan’s Nagoya University find and test a promising drug that stops cancer by interfering with the cancer cells’ metabolism and other circadian-related functions. (January 23, 2019)
On NPR’s Joe’s Big Idea, Andrea Armani and Samantha McBirney explain the inspiration behind their work on malaria and their progress toward an inexpensive and effective early-detection device. (January 17, 2019)
USC News reports that Ellis Meng is one of two USC faculty members elected to the elite organization, which works to increase the visibility of academic technology and innovation. (December 11, 2018)
Scientists at the USC Michelson Center for Convergent Bioscience and Stanford University have taken the first steps toward making a safer drug for reducing maternal mortality. (December 3, 2018)
After seeing how his mother dealt with the disease, Peter Kuhn tackles the toughest questions about cancer. Kuhn is a cancer researcher at the USC Michelson Center for Convergent Bioscience. He studies how cancer invades the human body.
A trio of USC Viterbi researchers have unlocked secrets about an engineered protein receptor, known as CAR, that makes cancer-fighting T cells more effective. Assistant Professor Stacey Finley, Professor Pin Wang and Assistant Professor Nick Graham have just published a paper that sheds light on how this new treatment works.
